MAPT and tauopathy: Like overexpressing amyloid mice, the PS19 mouse model of tauopathy, which carries the human tau P301S mutation, expressed microglial activation coinciding with synaptic pathology followed by fibrillary tau pathology and astrogliosis, while chemically or genetically enhanced microglial activation significantly accelerated tau pathology in hTau mice [240,241].